EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study

Peter Schellongowski iD, Michael Darmon, Philipp Eller, Laveena Munshi, Tobias Liebregts, Victoria Metaxa, Luca Montini, Tobias Lahmer, Fabio S Taccone, Andry van de Louw, Martin Balik, Peter Pickkers und 15 weitere

Intensive Care Medicine · 2025

DOI: 10.1007/s00134-025-08113-7 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Intensive Care Medicine, 2025. Verfasst von Peter Schellongowski und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria. peter.schellongowski@muv.ac.at. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, Neoplasms, Extracorporeal Membrane Oxygenation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Society of Intensive Care Medicine, Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Acute respiratory failure is the leading reason for intensive care unit (ICU) admission among critically ill patients with cancer. We aimed to describe the clinical characteristics, risk factors, and outcomes of patients with cancer and acute respiratory distress syndrome (ARDS) and to evaluate associations of venovenous extracorporeal membrane oxygenation (ECMO) with outcomes in the subgroup with severe ARDS. METHODS: We conducted a multinational, prospective, observational cohort study of patients with cancer and ARDS in 13 countries in Europe and North America. The primary endpoint was 90-day mortality. RESULTS: Among 715 included patients, 73.4% had hematologic malignancies and 26.6% solid tumors; 31.2% had undergone hematopoietic stem-cell transplantation (168 allogeneic). ICU, hospital, and 90-day mortality rates were 55.3%, 70.9%, and 73.2%, respectively. By multivariate analysis, independent predictors of higher 90-day mortality were older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and ICU admission as a time-limited trial (vs. full code). Conversely, lymphoma was associated with lower 90-day mortality. Among the 322 patients (45.7%) with severe ARDS at inclusion, 90-day mortality was 82.2%; with no difference between patients who received ECMO (n = 58, 18%) and those who did not (82.6% vs. 80.7%, P = 0.89). This finding remained unchanged in a double-adjusted overlap- and propensity-weighted Cox mixed-effects model (adjusted hazard ratio, 1.12; 95% confidence interval 0.65-1.94; P = 0.69). CONCLUSION: Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use. These findings suggest a need for nuanced ICU goals-of-care discussions and raise concerns about the generalizability of ECMO guidelines to this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Distress SyndromeNeoplasmsExtracorporeal Membrane OxygenationHumansMaleFemaleProspective StudiesMiddle AgedAgedIntensive Care UnitsRisk FactorsEuropeHospital MortalityNorth AmericaAdult

Stichwörter der Autor:innen

ArdsCancerEcmoLeukemiaLymphomaOutcome

Autor:innen und Institutionen

  • Department of Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria. peter.schellongowski@muv.ac.at.
  • Medical Intensive Care Unit, Hôpital Saint-Louis (AP-HP), and INSERM UMR1342, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.
  • Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Graz, Austria.
  • Department of Medicine and Interdepartmental Division of Critical Care Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
  • Department of Hematology and Stem Cell Transplantation, Intensive Care Unit, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany.
  • Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK.

ORCID-Profile: Peter Schellongowski

Förderung

  • European Society of Intensive Care Medicine
  • Medical University of Vienna

Zitieren

APA

Schellongowski, P., Darmon, M., Eller, P., Munshi, L., Liebregts, T., Metaxa, V., Montini, L., Lahmer, T., Taccone, F. S., van de Louw, A., Balik, M., Pickkers, P., Hemelaar, P., Yadav, H., Barratt-Due, A., Karvunidis, T., Riera, J., Martucci, G., Martin-Loeches, I., …, & YELENNA Investigators and the Nine-I Study Group (2025). Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study. Intensive Care Medicine. https://doi.org/10.1007/s00134-025-08113-7

Vancouver

Schellongowski P, Darmon M, Eller P, Munshi L, Liebregts T, Metaxa V, et al. Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study. Intensive Care Medicine. 2025. doi:10.1007/s00134-025-08113-7

BibTeX
@article{Schellongowski2025,
  author = {Schellongowski, Peter and Darmon, Michael and Eller, Philipp and Munshi, Laveena and Liebregts, Tobias and Metaxa, Victoria and Montini, Luca and Lahmer, Tobias and Taccone, Fabio S and van de Louw, Andry and Balik, Martin and Pickkers, Peter and Hemelaar, Pleun and Yadav, Hemang and Barratt-Due, Andreas and Karvunidis, Thomas and Riera, Jordi and Martucci, Gennaro and Martin-Loeches, Ignacio and Castro, Pedro and Buchtele, Nina and Lemiale, Virginie and Hatzl, Stefan and Dumas, Guillaume and Staudinger, Thomas and Azoulay, Elie and YELENNA Investigators and the Nine-I Study Group, YELENNA Investigators and the Nine-I Study Group},
  title = {Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study},
  journal = {Intensive Care Medicine},
  year = {2025},
  doi = {10.1007/s00134-025-08113-7}
}
Kostenlos starten →